(Q54278364)

English

Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells. (English)

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

0 references

1 reference

based on heuristic

inferred from title

author name string

E Kedar

1

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

Y Rutkowski

2

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

B Leshem

3

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

publication date

1 January 1992

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

35

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

63-68

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

1

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

https://scigraph.springernature.com/pub.10.1007/bf01741057

0 references

Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological response modifiers: the new immunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of interferon on adriamycin uptake of cultured tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferons in host defense

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy in combination with chemotherapy for cancer treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmented tumor-associated antigen expression by interferons

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine gene therapy for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene therapy for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic potential of cytokines: a comparison of preclinical and clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combining chemotherapy with biological response modifiers in treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer immunotherapy: are the results discouraging? Can they be improved?

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation and cloning of cytolytic T lymphocytes and their precursors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An explanation of the variable clinical response to interleukin 2 and LAK cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1611625

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01741057

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

1 reference

Europe PubMed Central

27 May 2018

http://europepmc.org/abstract/MED/1611625

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54278364&oldid=1380308489"